Shares of T2 Biosystems (NASDAQ:TTOO) have been assigned a consensus rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $5.94.
Several analysts recently weighed in on the stock. ValuEngine downgraded shares of T2 Biosystems from a “hold” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research cut shares of T2 Biosystems from a “buy” rating to a “hold” rating in a research note on Tuesday, April 3rd. HC Wainwright raised their target price on shares of T2 Biosystems from $8.00 to $8.50 and gave the company a “buy” rating in a research note on Thursday, March 29th. Finally, Goldman Sachs assumed coverage on shares of T2 Biosystems in a research note on Monday, January 29th. They set a “neutral” rating and a $5.20 target price on the stock.
NASDAQ:TTOO traded down $0.01 during mid-day trading on Wednesday, hitting $6.97. The stock had a trading volume of 162,395 shares, compared to its average volume of 190,566. T2 Biosystems has a 52 week low of $2.50 and a 52 week high of $7.53. The company has a current ratio of 0.86, a quick ratio of 0.83 and a debt-to-equity ratio of 1.29.
TRADEMARK VIOLATION WARNING: “T2 Biosystems (TTOO) Receives $5.94 Average PT from Brokerages” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3377248/t2-biosystems-ttoo-receives-5-94-average-pt-from-brokerages.html.
T2 Biosystems Company Profile
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.